Definium Therapeutics Launches ‘Wired For Worry,’ HCP Education Initiative For GAD
Definium Therapeutics, Inc., a late-stage clinical biopharmaceutical company developing therapeutics aimed at underlying causes of psychiatric and neurological disorders, launched Wired for Worry, a disease education initiative for health care professionals. The initiative is increasing health care professionals' understanding of generalized anxiety disorder (GAD).
The initiative provides education on GAD, including how the disorder may result from dysregulated brain circuitry that contributes to chronic symptoms and functional impairment. It also emphasizes the use of the Generalized Anxiety Disorder-7 (GAD-7) screening scale to support consumer identification and outcomes. According to the company, GAD can significantly affect daily life . . .
